Development of a Novel Therapy to Inhibit the Progression and Metastasis of Stomach Cancer
Abstract
This proposed research will address the Fiscal Year 2020 (FY20) Peer Reviewed Cancer Research Program Topic Area: Stomach Cancer and Military Health Focus Areas: (1) Gaps in cancer treatment, and (2) Militarily-relevant risk factors associated with cancer (infectious agent). Since recent reports indicate that vascular endothelial growth factor–C (VEGF-C) promotes invasion of cancer cells, and because VEGF-C also induces lymphangiogenesis (a process by which new lymphatics are formed from preexisting lymphatic vasculature) by acting mainly through its vascular endothelial growth factor receptor-3 (VEGFR-3) present in lymphatic endothelial cells is associated with lymph node (LN) metastasis in gastric cancer, we therefore hypothesize that targeting VEGF-C actions will inhibit progression and LN metastasis in this disease. As our serendipitous findings further indicate that low, non-toxic concentration/dose of DAD3 receptor (DAD3R) agonists can significantly inhibit the functions of VEGF-C both in vitro and in vivo (unpublished data), we will, therefore, investigate the effects of treatment with DAD3R agonists on the prevention or inhibition of progression and LN metastasis in well-established preclinical mouse models simulating the lesions observed in human patients suffering from the intestinal type of gastric cancer, the most common type of gastric cancer seen in the world. Our study may identify a new and effective therapeutic approach to target progression and LN metastasis, especially in localized gastric cancer in patients, including active-duty Service Members, Veterans, and their family members.
Document Details
- Document Type
- DoD Grant Award
- Publication Date
- Dec 05, 2021
- Source ID
- W81XWH2110874
Entities
People
- Sujit Basu
Organizations
- Ohio State University
- United States Army